Colombia Gastric Cancer Drugs Market - Industry Trends and Forecast to 2029

Colombia gastric cancer drugs market is projected to register a substantial CAGR of 8.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Colombia Gastric Cancer Drugs Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma, and Others), Stage (Stage III, Stage II, Stage IV, Stage I, and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the Colombia gastric cancer drugs market are:

• Rising Prevalence of gastric cancer
• Increasing technological advancements

Market Players:

The key market players for Colombia gastric cancer drugs market are listed below: 

• Bayer AG
• Novartis AG 
• Pfizer Inc.
• Celltrion Healthcare Co., Ltd. 
• F. Hoffmann-La Roche Ltd 
• Merck KGaA 
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• AstraZeneca
• Viatris Inc.
• Bristol-Myers Squibb Company
•  Concord Biotech 
• GlaxoSmithKline plc.